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1" Introduction
TS is a key enzyme in the de novo synthesis of dTMR an
e ssential precursor of DNA, which catalyses the methylation
of dUMP to dTMP [1].
The critical role of TS in the nucleotide metabolism has
n.rade it an important target of a variety of chemotherapeutic
ager.rts including 5-FU, 5-FU prodrugs as capecitabine, and
novel fblate-based TS inhibitor such as raltitrexed and
L.ernetrexed, used in the treatment of colorectal and other
solid tumours [2]. Resistance to fluoropyrimidines and other
TS inhibitors may occur through a variety of mechanisms
including elevated intracellular TS ievels resulting from
increases in TS transcription [3] and translation [4].
in CRC patients the TS intratumoural expression may
predict fbr the sensitivity to 5-FU and other TS inhibitor-
based chemotherapies [S, 0] and may also be an importanr
prognostic marker [71. High TS expression in early stage
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Thymidylate synthase (TS) catalyzes methylation of dUMP to dTMP and it is the target for the 5-Fluorouracil (5-FU) activity*.
Barbour et al. showed that variant structural forms of TS in tumour cell lines confer resistance to fluoropyrimidines. We planned
to perform the whole TS gene structure by means of sequencing techniques in human colorectal cancer (CRC) san-rples to try to
identify the presence of any possible TS variant form that could be responsible of fluoropyrimidines drug resistance and of the
worse prognosis. We performed the TS-DNA gene sequence in 68 CRC from patients of A, B, and C Dukes' stages and different
histological grade, but we did not find any mutation in the TS-DNA structure. In the future we intend to widen the TS structure
analysis to the metastatic CRCs, because due to their higher genomic instability, they could present a TS variant form responsilile
of the fluoropyrimidines drug resistance and the worse prognosis.
CRC patients seems to predict for poorer overall survival irr
both chemotherapy-treated and untreated patients follorving
surgery [4] . Also, metastatic CRC patients with high TS
levels are unlikely to respond to infusional treatment with
5-FU, whereas patients with low TS levels have higher than
average response rate [8, 9]. In a previous study, holvever, rve
demonstrated that higher TS levels are favourable prognostic
factors for disease free and overall survival [10]. To date the
real value ofthe TS level as prognostic factor is doubtful and
some authors are in disagreement about it [1 1]. The TS gene,
containing 7 coding exons, is located in chromosome i8q,
for which a high percentage of monosomic loss has been
reported to be cell-cycle dependent, although some recent
evidence points are more oriented towards proliferation-
dependence. It can be predicted that mutations in the TS
gene might result in a modification of its structure and
then in its ability to interact with the fluoropyrimidines.
This prediction has been born out in a variety of studies
Tanlr 1: Clinical features ofpatients
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Teslc 3: Tumour staging and grading.
No. of patients
lvledian age
Sex
Male
Female
68
67
30
38
Tttmour staging
Dukes A
Dukes B
Dukes C
i0
27
31
T,rsr-l 2: Site of primary tumour.
Grading
î1\fl
G3
7
36
25
Right colon
Left colon
Rectur.rr
21
34
13
[12-15]. S. H, Berger and F. G. Berger reported that
the human colon tumour cell line HCTll6 produces a
variant structural form of TS, in addition to the common
form found in all coìon cell lines tested. Among the TS
overproduction derivatives of HCT116, cells overexposing
the novel forms are more resistant to FdUrd, compared
with ceils overexpressing the normal form [15]. So, an
association between drug response and altered TS structure
could suggest that the novel TS form, which is encoded
by a variant structural TS gene, confers relative resistance
to FdUrd [1]; this was supported by preliminary kinetic
data indicating that this novel form has a reduced affinity
for FdUMP [16]. This variant form presents a replacement
of an evoÌutionary conserved tyrosine by a histidine at
residue 33 of the TS polypeptide [17, 18]; this muration
represents the only difference between the two TS forms and
must account for the structural and functional differences
between them. In an our previous paper we performed the
analysis of the TS structure in patients bearing CRC to try
to demonstrate the presence of that specific mutation, but
we did not find it in any patient [19]. Here, we intend to
proceed on the use of sequencing techniques to see if any
TS variant form could be present in human cancer samples
fron patients who underwent surgery for primary colorectal
cancer and previously untreated and try to flnd relationship
between any hypothetical TS variant form with the 5-FU
treatment.
We performed the TS-DNA gene sequence in 68 cancer
sampìes from patients of different Dukes' stages (A, B, and
C) and histological grade but we did not find any change in
the TS-DNA structure.
2. Materials and Methods
2.1. Patients. TS structure was assessed in a series of 68
patients who underwent surgery for primary colorectal car-
cinoma confirmed histologically and previously untreated.
The following exclusion criteria were applied: history of
other neoplasias apart of CRC and death occurring within
30 days following surgery and due to postoperative com-
plications. The tumours were staged and graded according
Dukes' system and their clinicopathological features were
summarised in Tables l, 2, and 3.
T,qsLp 4: Primer sequences.
Prim name Primer sequence
Ir,
1R
zl
2R
3F
,t(
4F
4R
5F
5R
6F
6R
7F
7R
CGCCGCGCCACTTCGC
CTCCCCAGCCGCGCCTCC
GGAIGGCATGATCTGTC
CTGCTGTGTTGAGAACAG
CAACTGAGATGGCTTAAG
GCAAACACGTGCTAGGAAGG
GCCATCTCATGACATG
CCCTCAGTGCCTCTGCAC
CTTTGCCTTTAGCTGTG
GAGCTCATGTGGTAGGCT
GCGGTGTCTGCATATT
GCATTGAGCAGATACCTG
CACGGACATGAGGAGC
CTAAAGACTGACA.{]]{|C
2.2. Colorectal Tumour Samples. Primary tumour and cor-
responding colonic mucosa were obtained with informed
consent from patients. The samples at surgery were divided
in two parts: one was frozen at 
-80' until analysis, and
the other portion was embedded in paraffìn to corìfirn
histologically the absence of contamination by normal and
necrotic tissue and lymphocl'tes.
2.3. Extraction of Genomic DNA, PCR Analyses, and Sequenc-
lng. Genomic DNA was extracted from tumour and mucosa
samples with a commercial Kit purchased from Qiagen
(Kjvenlo, The Netherlands) and stored at 
-20".
The TS gene of tumour and mucosa samples was ampli-
fied in seven different PCR reactions using DNA primers of
l6-20 bases in length placed in the adjacent intronic regions
of exons 1, 2, 3, 4,5, 6, and 7 and listed in Table 4.
Amplification was performed using a Perkin Elmer
model 2400 thermal cycler (Boston USA). Reaction mixture
included 5 pL of 10olo dimethylsulfoxide, 5 pL of 10 x buftèr,
l.5pL oî l.5mM MgClr, l1L of 10mM dNTPs, 200-
500ng of genomic DNA, 200pmol of both upstream alrd
downstream primers, and 1 Units of Taq DNA polymerase,
in a final volume of 50 yL. Amplification was run for 35
cycles with each cycle consisting in a denatufation step at
95'C for l minutes, a primer annealing step at 51"C for
I minute, and an extention step at 72'C for 2 minutes.
PCR was terminated by incubatio n at 72' C for 10 minutes.
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The length of the amplification products ranged from 180 to
310 bases. Amplified fragments were analysed by agarose gel
and visualized by ethidium bromide staining' DNA samples,
generated with independently repeated PCR products, were
sequenced rvith the SequiTherm EXCEL II DNA sequencing
kit (Epicenter, Madison, WI) on a LI-COR 4000 (MWG-
Biotech, Ebersberg, Germany) sequenceÍ.
3. Results
The enzyme structure obtained by sequencing the TS
genomic DNA of each sample was performed in 68 patients
with operable CRC, untreated with previous chemotherapy.
Prinrary tumours and corresponding colonic mucosa were
obtained frorl each patient and the TS genomic structure
was performed on each of them, aÍÌer histological control.
7 patients had Gl histological grade, 36 had G2, and 25 had
G3 histological grade; 10 patients had Dukes'A tumours, 27
patients had Dukes' B, and 31 patients had Dukes C cancers.
The rnedian age of patients was 67 years; 30 patients were
rnale and 38 female. In all the tumour samples evaluated
n'e did not find any TS-DNA variant structure in tumour:
all A, B, and C Dukes'patients showed stable TS-DNA, and
also in the germline genome no TS-DNA variants have been
observed.
4. Discussion
The structure of the macr-omolecular target of a cytotoxic
drug is a critical determinant of cellular sensitivity to that
drug. Recently, TS has become the subject of severaì studies
aimed to elucidate a possible "clinical" role of TS detection
either as determinant of drug resistance or as prognostic
marker of the disease and predictive factor of the treatment.
Many studies are currently examining the real value of
TS expression levels as a prognostic factor, but in the mean
time significant uncertainty prevails; whatever its prognostic
influence, to date no studies have been able to estabiish a
"cut-off" that is important for clinical usage. On the whole,
alÌ of these in vitro studies have promising implications in
tire study of the role of TS in clinical practice.
Moreover, the unclear meaning of "levels" not only as
a prognostic indicator but also as marker predictive of
resistance could be due to mechanisms different from over
expression, as mutation.
In fact some authors focused their attention on the TS
structure with a double aim: development of a new classes
of TS-inhibitors with a different mechanism of action and
generation of TS mutants to deveìop gene-therapy strate-
gies. Berger and coworkers showed that a single naturally
occurring change, a Tyr to His replacement, in the prirnary
structure of the TS molecule confers relative resistance to the
TS-directed antimetabolite FdUrd in HCT I l6 cells. The Tyr
to His mutation is the only difference between the altered
form of TS and the normal form and, therefore, must be
responsible for the diminished effectiveness of the enzyme
as a drug target.
The data in those studies, together with previously
published experiments, strongly favour the notion that the
I
Tyr to His' mutation is responsible fbr the relative FdUrd
resistance of cell line HCT 116 [15, 16]. However, as
noted earlier, it is quite possible that làctors in addition
to this mutation contribute to the phenotype of HCTl16
and other colon celi lines. The frequency of the Tyr33
to His33 mutation in the norrnal and in the pathological
human popuiations is unknown. The altered TS may exist
as a polymorphism in humans Ii6]; alternatively, it may
have spontaneously arisen during tur"trorigenesis or during
establishment of the cell lines in culture.
Distinguishing among these possibilìties will be of great
utility in assessing whether variant forms of TS identified in
cultured cell lines are segregating in the human population
and have an impact upon clinical response to 5-fluorouracil
therapy in cancer patients. On the basis of this knowledge we
hoped to see if in human CRC samples it could be possible
to find the same Tyr33 to His33 substitution in the TS
structure and eventually to correlate this finding with some
clinicopathological parameters such as age and sex, tumour
size and location, histological grade, Dukes' stage, 5-FU and
Raltitrexed treatment, and disease free and overail survivals,
to see if that point mutation could be considered a reliable
marker of drug resistance and of prognosis. In those samples
we did not find that point mutation at the codon 33 [19].
In this study we intend to proceed ou the nse of
sequencing techniques to see if any TS variant for-m could
be present in human cancer samples from patients u'ho
underwent surgery for primary colorectal cancer (CRC) and
previousiy untreated and try to find a relationship betlveen
any hypothetical TS variant form with the 5-FU treatment
and prognosis.
We performed the TS-DNA gene sequence in 68 cancer
samples from patients of different Dukes'stages (A, B, and C)
and histological grade, but we did not find any mutation in
the TS-DNA structure. The conclusions that could be drown
are that in Dukes'A, B, and C CRCs there are no changes in
the TS-DNA gene structure and that the evaluation of the TS
expression is the main CRC prognostic and drug response
marker. What remains is to evaluate the TS gene structure
of the D metastatic Dukes' CRCs: in these tumours it
might be possible to find TS-DNA structural changes related
with their higher genomic instability and this fact could
give an explanation of the 5-FU drug resistance and rvorse
proSnosls.
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